Conference abstractPublished 6 Dec 2017
Preclinical researches on novel sugar dendritic Gd-DTPA MRI contrast agents and IER5/Cdc25B targeted phospha sugar antitumor agents to innovate in cancer therapy
Shizuoka University, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Innovative and strategic materials against tumor cells to decrease sharply the number of dead people by tumors are desired eagerly. To innovate in medical technologies of diagnosis and cure for various kinds of tumors by novel medicinal materials, i.e., sugar dendritic Gd-DTPA complex MRI contrast agent (DEN-OH) and IER5/Cdc25B targeted novel phospha sugar antitumor agents (TBMPP) were prepared and evaluated in vitro and in vivo methods, and then these novel medicinal materials were revealed preclinically to have excellent characters against tumor cells.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- SubjectRadiology & Imaging
- BylineArticles whose byline prints “Mitsuji Yamashita”